Cynthia Turner

Shannon Associates

Activated Platelets in aHUS 

Prev Next
Previous

MOA- Blocking the Immune Checkpoint Inhibitor

medical illustration of Atypical Hemolytic Uremic Syndrome (aHUS) manifests by chronic uncontrolled complement activation leading to the continuous activation of platelets and endothelial cells. The resulting thrombi cause thrombotic microangiopathy which may result in sudden fatal thrombotic complications or in the progressive failure of vital organs, including the kidney, heart, and brain. For Alexion Pharmaceuticals.
Next medical illustration of The neurovascular unit for Remedy Pharmaceuticals investor relations. Remedy’s drug candidate reduces brain swelling and hemorrhage following traumatic injury. The brain microvessels, astrocytes, pericytes, neurons, microglia and the extracellular matrix form functional neurovascular units to maintain a precisely regulated microenvironment for reliable neuronal signaling.

The Neurovascular Unit

Atypical Hemolytic Uremic Syndrome (aHUS) manifests by chronic uncontrolled complement activation leading to the continuous activation of platelets and endothelial cells. The resulting thrombi cause thrombotic microangiopathy which may result in sudden fatal thrombotic complications or in the progressive failure of vital organs, including the kidney, heart, and brain. For Alexion Pharmaceuticals.

Keywords: Airbrush, Color, 3D, Advertising / Marketing, Biotechnology, Cell biology / Histology, Disease Management, Pharmacology, Hemophilia

© Cynthia Turner